Navigation Links
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Date:3/11/2009

>

Patients receiving PEGINTRON and REBETOL as retreatment after failing a previous interferon combination regimen reported adverse reactions similar to those previously associated with this regimen during clinical trials of treatment-naive patients.

About Hepatitis C

Hepatitis C is a serious and potentially life-threatening disease. It is the most common blood-borne infection in America and the most common form of liver disease, affecting nearly 5 million people in the United States alone. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States.

About PEGINTRON

In the United States, PEGINTRON is indicated for use in combination with ribavirin in patients 3 years of age or older, and as monotherapy in patients 18 years of age and older, for the treatment of chronic hepatitis C in patients with compensated liver disease. Patients with the following characteristics are less likely to benefit from retreatment after failing a course of therapy: previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and genotype 1 infection.

Important Safety Information Regarding U.S. Labeling for PEGINTRON and REBETOL

Alpha interferons, including PEGINTRON, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many, but not all cases, these disorders resolve after stopping PEGINTRON therapy.

Use with Ribavirin: Ribavirin may cause birth defects and death of the unborn child. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin ca
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Scientific Corporation (NYSE: BSX ) today announced ... Connors as a Director. ,, Ms. Connors, ... division of Tyco International. Previously, she served as ... operations and general management. Prior to Eaton, Ms. ... management capacities with Ford, Chrysler and Mogami Denki, a ...
(Date:12/16/2009)... Siemens Healthcare today announced a series ... to help healthcare providers pursue meaningful ... the HITECH provision of the American Recovery ... zero-percent interest terms for qualified customers, the ... associated with their technology investment while meeting ...
(Date:12/16/2009)... Dec. 16 BioSpecifics Technologies Corp. (Nasdaq: ... in class collagenase-based products, today announced top-line efficacy ... trial of XIAFLEX(TM) for the treatment of Peyronie,s ... of inelastic collagen on the shaft of the ... sexual intercourse difficult or impossible in advanced cases. ...
Breaking Medicine Technology:Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 2Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 2Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 4BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4The American Society of Human Genetics to Host Press Briefing on 26apos 3BPersonalized Medicine and the Future of Health Care Practice 26apos 3B at 5 59024 1The American Society of Human Genetics to Host Press Briefing on 26apos 3BPersonalized Medicine and the Future of Health Care Practice 26apos 3B at 5 59024 2The American Society of Human Genetics to Host Press Briefing on 26apos 3BPersonalized Medicine and the Future of Health Care Practice 26apos 3B at 5 59024 3The American Society of Human Genetics to Host Press Briefing on 26apos 3BPersonalized Medicine and the Future of Health Care Practice 26apos 3B at 5 59024 4Southern California Renaissance Laser and Vein Institute 28laserandveinclinic com 29 Offers Cutting Edge New Titan Procedure 59019 1Southern California Renaissance Laser and Vein Institute 28laserandveinclinic com 29 Offers Cutting Edge New Titan Procedure 59019 2Michigan Dentist Chosen President Elect of the American Dental Association 59015 1Michigan Dentist Chosen President Elect of the American Dental Association 59015 2
... ASCT and warrant ... ... (Nasdaq and MTAX: CTIC) announced today that results of a ... demonstrate,that the addition of radioimmunotherapy (RIT) to high-dose chemotherapy,(HDC) followed ...
... FRANCISCO, Calif., Jan. 16 Cerimon,Pharmaceuticals, Inc., announced ... II/III clinical studies of its once-,daily topical diclofenac ... One,of the studies, designated the "SUPPORT" (Stop Underlying ... study, will assess the,efficacy and safety of Cerimon,s ...
Other Medicine Technology:Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma 2Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma 3Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma 4Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain 2Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain 3
(Date:12/16/2009)... to Quality, Cost-Effective Care , ... Washington, D.C. (Vocus) ... the best ways to rein in runaway costs while providing care ... part of the ongoing discussion includes how to ensure patients equal ... of medicine (MDs) or osteopathy (DOs). In both the House ...
(Date:12/16/2009)... of Digital Pen and Paper technology and the provider of ... announced that it is ranked among the Fastest Growing Technology ... , ... (PRWEB) December 16, 2009 ... the capture, digitalization and management of handwritten data. Kayentis targets ...
(Date:12/16/2009)... for use, expert says, , , WEDNESDAY, Dec. 16 (HealthDay ... less likely to die when they receive an implantable ... included 4,685 people, ages 65 to 85, who were ... fraction (a measure of the heart,s pumping ability) of ... those who were treated with standard medication and an ...
(Date:12/16/2009)... Dec. 16 Shoppers like knowing if ... or Argentina. But grocers have found it burdensome ... (COOL) laws requiring them to provide the information ... at easyCOOLnow.com for easily making grocery ... include provisions that require retailers of unprocessed fruits, ...
(Date:12/16/2009)... new software program developed by CareRise will reduce the ... their staffing needs as it relates to the patient ... facilities to calculate their mandatory nurse-to-patient staffing needs, comply ... daily report as to how it affects their bottom ... management in the healthcare industry, has been allowed a ...
Breaking Medicine News(10 mins):Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2Health News:Implanted Defibrillator Might Extend Life 2Health News:New Website Helps Grocers Comply With COOL Laws 2Health News:United States Patent Office Allows CareRise Patent on 24/7 Staff-Census Software 2
... Mobility Program Helps Eden Home Resident regain mobility and,Be Active, ... a "sweetheart with a sweet tooth" say his friends at ... borrowed power wheelchair,from delivering mail at the facility where the ... "chocoholic." To keep him on the,go, The SCOOTER Store has ...
... in Place, also a,Priority, ALBANY, N.Y., Feb. 6 ... accept the Governor,s proposal to,create a prescription drug discount ... of prescription drugs to lower costs for,taxpayers and New ... budget hearing on "Health, Medicaid and Aging.", "These ...
... 10 Minnesotans diagnosed with a mental illness, ST. ... Plans today released the first and most comprehensive,overview of ... Mental Health, were released today at the Mental Health,Innovations ... to create greater understanding of mental health,in our state ...
... multiple risk factors at once, , , WEDNESDAY, Feb. 6 (HealthDay ... showing signs of some kidney damage may be able to ... factors at once. , That,s the conclusion of a ... the New England Journal of Medicine , that found ...
... Very young brains process memories of fear differently than ... the Feb. 6 issue of The Journal of Neuroscience ... how fear is stored and unlearned, and introduces new thinking ... This important paper raises questions that are the tip of ...
... (AGHE) will hold its 34th Annual Meeting and ... Renaissance Harborplace Hotel in Baltimore, MD. Media representatives ... year,s Distinguished Teacher Lecture Series will focus on the ... education about aging. , GEROTOOBE: Discovering the Aging ...
Other Medicine News:Health News:The SCOOTER Store Donates Power Wheelchair to New Braunfels Car Crash Victim 2Health News:AARP Testifies in Favor of Bulk Buying and Rx Card Proposals in Executive Budget Proposal 2Health News:New Report Offers Comprehensive Look at Mental Health in Minnesota 2Health News:Aggressive Diabetes Therapy Lowers Death Risk, Study Finds 2Health News:Aggressive Diabetes Therapy Lowers Death Risk, Study Finds 3Health News:Very young found to process fear memories in unique way 2Health News:Gerontology conference's highlights to include talks on student social networking 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: